LDHB

Summary

LDHB (lactate dehydrogenase B, HGNC:6541) is a protein-coding gene on chromosome 12p12.1, encoding L-lactate dehydrogenase B chain (P07195). Interconverts simultaneously and stereospecifically pyruvate and lactate with concomitant interconversion of NADH and NAD(+).

This gene encodes the B subunit of lactate dehydrogenase enzyme, which catalyzes the interconversion of pyruvate and lactate with concomitant interconversion of NADH and NAD+ in a post-glycolysis process. Alternatively spliced transcript variants have been found for this gene. Recent studies have shown that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is localized in the peroxisomes. Mutations in this gene are associated with lactate dehydrogenase B deficiency. Pseudogenes have been identified on chromosomes X, 5 and 13.

Source: NCBI Gene 3945 — RefSeq curated summary.

At a glance

• Gene–disease (curated): glycogen storage disease due to lactate dehydrogenase H-subunit deficiency (Supportive, GenCC)
• GWAS associations: 1
• Clinical variants (ClinVar): 68 total
• Phenotypes (HPO): 1
• Druggable target: yes — 2 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_002300

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6541
Approved symbol	LDHB
Name	lactate dehydrogenase B
Location	12p12.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000111716
Ensembl biotype	protein_coding
OMIM	150100
Entrez	3945

Gene structure

Transcript identifiers

Ensembl transcripts: 25 — 20 protein_coding, 4 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000350669, ENST00000396075, ENST00000396076, ENST00000450584, ENST00000470280, ENST00000470985, ENST00000535112, ENST00000539782, ENST00000542765, ENST00000544151, ENST00000673047, ENST00000895165, ENST00000895166, ENST00000895167, ENST00000895168, ENST00000895169, ENST00000895170, ENST00000895171, ENST00000915334, ENST00000915335, ENST00000915336, ENST00000915337, ENST00000944678, ENST00000944679, ENST00000944680

RefSeq mRNA: 6 — MANE Select: NM_002300 NM_001174097, NM_001315537, NM_001414233, NM_001414234, NM_001414235, NM_002300

CCDS: CCDS8691, CCDS91663

Canonical transcript exons

ENST00000350669 — 8 exons

Exon	Start	End
ENSE00000726193	21638353	21638470
ENSE00000726197	21641952	21642125
ENSE00000726202	21643935	21644108
ENSE00000822271	21654543	21654677
ENSE00001363843	21657751	21657842
ENSE00003488101	21646899	21647016
ENSE00003491512	21637071	21637194
ENSE00003526630	21635342	21635709

Expression profiles

Bgee: expression breadth ubiquitous, 293 present calls, max score 99.95.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 455.4918 / max 5611.8436, expressed in 1729 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
130037	285.5723	1723
130036	169.4647	1713
130030	0.2794	109
130033	0.0811	10
130032	0.0611	8
130031	0.0222	11
130038	0.0066	5
130039	0.0045	4

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
renal medulla	UBERON:0000362	99.95	gold quality
heart right ventricle	UBERON:0002080	99.93	gold quality
lateral globus pallidus	UBERON:0002476	99.93	gold quality
endothelial cell	CL:0000115	99.92	gold quality
substantia nigra pars compacta	UBERON:0001965	99.91	gold quality
lateral nuclear group of thalamus	UBERON:0002736	99.91	gold quality
left ventricle myocardium	UBERON:0006566	99.91	gold quality
substantia nigra pars reticulata	UBERON:0001966	99.90	gold quality
nephron tubule	UBERON:0001231	99.89	gold quality
pons	UBERON:0000988	99.87	gold quality
apex of heart	UBERON:0002098	99.87	gold quality
myocardium	UBERON:0002349	99.87	gold quality
middle temporal gyrus	UBERON:0002771	99.87	gold quality
superior vestibular nucleus	UBERON:0007227	99.87	gold quality
adult mammalian kidney	UBERON:0000082	99.86	gold quality
cardiac ventricle	UBERON:0002082	99.85	gold quality
heart left ventricle	UBERON:0002084	99.85	gold quality
Brodmann (1909) area 23	UBERON:0013554	99.85	gold quality
ventral tegmental area	UBERON:0002691	99.83	gold quality
cranial nerve II	UBERON:0000941	99.82	gold quality
kidney	UBERON:0002113	99.81	gold quality
postcentral gyrus	UBERON:0002581	99.81	gold quality
Brodmann (1909) area 46	UBERON:0006483	99.81	gold quality
pigmented layer of retina	UBERON:0001782	99.80	gold quality
parietal lobe	UBERON:0001872	99.80	gold quality
medulla oblongata	UBERON:0001896	99.80	gold quality
dorsal plus ventral thalamus	UBERON:0001897	99.80	gold quality
superior frontal gyrus	UBERON:0002661	99.80	gold quality
metanephros cortex	UBERON:0010533	99.80	gold quality
globus pallidus	UBERON:0001875	99.79	gold quality

Single-cell (SCXA)

Detected in 47 experiment(s), a significant marker in 27.

Experiment	Marker?	Max mean expression
E-HCAD-10	yes	2228.73
E-MTAB-9067	yes	1992.70
E-GEOD-84465	yes	1760.22
E-GEOD-130473	yes	1610.68
E-HCAD-4	yes	1555.03
E-CURD-112	yes	1440.98
E-MTAB-10042	yes	1421.42
E-MTAB-5061	yes	1301.24
E-MTAB-9801	yes	1201.86
E-HCAD-8	yes	993.34
E-CURD-122	yes	802.46
E-MTAB-9221	yes	669.17
E-MTAB-6701	yes	118.51
E-HCAD-1	yes	100.47
E-CURD-114	yes	74.03

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ESRRA, MYC

miRNA regulators (miRDB)

20 targeting LDHB, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-139-5P	99.80	69.50	1399
HSA-MIR-4679	99.76	69.19	1229
HSA-MIR-4677-3P	99.49	67.91	1246
HSA-MIR-330-3P	99.41	69.95	2521
HSA-MIR-513A-3P	99.39	70.63	3620
HSA-MIR-513C-3P	99.39	70.63	3620
HSA-MIR-6739-3P	99.22	68.84	1843
HSA-MIR-3606-3P	99.11	69.84	3254
HSA-MIR-375-3P	97.91	65.12	483
HSA-MIR-1279	97.83	67.50	1898
HSA-MIR-335-5P	97.10	68.12	1022
HSA-MIR-6854-5P	96.77	65.96	848
HSA-MIR-4509	96.19	65.80	900

Literature-anchored findings (GeneRIF, showing 40)

• LDHB was elevated in idiopathic myelofibrosis. This isoenzymatic pattern could be expression of a metabolic adaptation. (PMID:17178662)
• MYC, LDHB, and CCNB1 may have roles in progression of medulloblastoma (PMID:18593994)
• Elevated serum LDH isoenzymes and AST indicate a disturbance (of uncertain clinical significance) within multiple extraosseous tissues when there is CLCN7 deficiency. (PMID:20499337)
• S100B and LDH are not expressed in sentinel node progression of melanoma (PMID:20592382)
• Presented are QM/MM calculations that show differences in geometries of active sites of M(4) and H(4) isoforms of human LDH ligated with oxamate, pyruvate or L-lactate. (PMID:20951115)
• findings offer proof of concept for targeting LDHB as a therapeutic strategy in cancers driven by aberrant activation of the RTK-PI3K-AKT-mTOR signaling cascade (PMID:21199794)
• Results suggest that lactate dehydrogenase B suppression plays an important role in triggering or maintaining the mitochondrial defects and then contributes to cancer cell invasiveness by inducing claudin-1 protein. (PMID:21356207)
• Results show that S-100B, MIA and LDH levels were significantly higher in patients with advanced melanoma than in disease-free patients or healthy controls. (PMID:21858537)
• results confirmed the prognostic roles of LDH-B in urinary bladder urothelial carcinoma. (PMID:22027740)
• The significant elevation in serum CK [creatine kinase ]and LDH [L-Lactate Dehydrogenase ] activities indicates that these can be used as parameters for screening hypothyroid patients but not hyperthyroid patients. (PMID:22248949)
• Data indicate that serum lactate dehydrogenase (LDH) seemed able to predict clinical outcome for hepatocellular carcinoma (HCC) patients undergoing hepatocellular carcinoma (HCC). (PMID:22461886)
• results indicate that histone deacetylase inhibitors upregulate miRNAs, at least some of which act as tumor suppressors. lactate dehydrogenase B, which is regulated by the tumor suppressive miR-375, may therefore act as an oncogene in esophageal squamous cell carcinoma. (PMID:22752059)
• Serum lactate dehydrogenase is a prognostic and predictive biomarker for survival benefit conferred by TORC1 inhibition in poor-risk renal cell carcinoma. (PMID:22891270)
• Patients with severe vaso-occlusive crisis were more frequently males, who also had higher white blood cell (WBC) count, procalcitonin (PCT), and lactate dehydrogenase (LDH) levels. (PMID:22892192)
• Data reveal that LDHB is upregulated and required only in certain cancer genotypes. (PMID:23139210)
• LDH concentrations in nasopharyngeal secretions are positively associated with acute otitis media risk. (PMID:23202721)
• This study identifies LDHB as a regulator of cell proliferation in a subset of lung adenocarcinoma and may provide a novel therapeutic approach for treating lung cancer (PMID:23224736)
• ata indicate that serum lactic dehydrogenase (S-LDH) appears to be a significant independent prognostic index in patients with metastatic nasopharyngeal carcinoma (NPC). (PMID:23266049)
• Loss of LDH-B expression is an early and frequent event in human breast cancer occurring due to promoter methylation, and is likely to contribute to an enhanced glycolysis of cancer cells under hypoxia. (PMID:23437403)
• the role played by ERRalpha in the regulation of lactate dehydrogenases A and B (PMID:23516535)
• These observations support prospective clinical evaluation of LDHB as a predictive marker of response for patients with breast cancer receiving neoadjuvant chemotherapy. (PMID:23697991)
• The PFK2 expression along with LDH-4 were observed to be increased ~2-fold (P < 0.001) in 0.5 mM ammonia treated brain slices. (PMID:23703029)
• This meta-analysis shows that high serum LDH level is obviously associated with lower overall survival rate in patients with osteosarcoma, and it is an effective biomarker of prognosis. (PMID:24682390)
• We were able to provide evidence that methylation of HLTF and especially HPP1 detected in serum is strongly correlated with cell death in CRC using LDH as surrogate marker (PMID:24708595)
• The readthrough-extended lactate dehydrogenase subunit LDHBx can also co-import LDHA, the other LDH subunit, into peroxisomes. (PMID:25247702)
• In this study, we inhibited LDH using oxamate resulting in the inhibition of proliferation and induction of apoptosis in gastric cancer (PMID:25524555)
• Lactate dehydrogenase B is associated with the response to neoadjuvant chemotherapy in oral squamous cell carcinoma. (PMID:25973606)
• addition of exogenous lactic acid to growth media was sufficient to induce cell death that could be inhibited by the expression of LDHB. the results suggest that lactate dehydrogenase is a general suppressor of programmed cell death in yeast. (PMID:26032856)
• The aim of this study was to demonstrate the effects of 6-week low-intensity training on changes in indicators of aerobic capacity and on HSPA1A, HSPB1, and LDHb expression in white blood cells in high level rowers. (PMID:26214432)
• our study examines the inclusion of salivary LDH as potential diagnostic parameter and therapeutic index in Oral squamous cell carcinoma (PMID:26577856)
• this study shows that low base line lactate dehydrogenase is linked with a better tumor response, and that prolonged overall survival and progression-free survival are observed for patients under ipilimumab treatment with no increase in lactate dehydrogenase (PMID:27485076)
• High LDHB expression is significantly associated with the level of serum LDH and better clinical outcomes in lung squamous cell carcinoma (PMID:28756978)
• Our results indicate that ectopic FGFR1 expression reprograms the energy metabolism of prostate cancer cells, representing a hallmark change in prostate cancer progression. FGF signaling drives the Warburg effect through differential regulation of LDHA and LDHB, thereby promoting the progression of prostate cancer (PMID:29891507)
• Knockout of both LDH-A and LDH-B leads to suppression of glycolysis. (PMID:30158244)
• SIRT5-induced deacetylation of LDHB triggers hyperactivation of autophagy, a key event in tumorigenesis. (PMID:30443978)
• LDHA and LDHB are dispensable for aerobic glycolysis in neuroblastoma cells while promoting their aggressiveness. (PMID:30610122)
• These results suggest that LDHB suppression is a key mechanism that enhances glycolysis and is critically involved in the maintenance and propagation of mitochondrial dysfunction via lactate release in liver cancer progression. (PMID:30923124)
• Diagnostic value of procalcitonin, C-reactive protein and lactate dehydrogenase in paediatric malignant solid tumour concurrent with infection and tumour progression. (PMID:30976022)
• Study demonstrated that miR-335-5p regulates cell proliferation, migration as well as invasion of CRC cells through down-regulating LDHB (PMID:31424671)
• rs11046147 mutation in the promoter region of lactate dehydrogenase-B as a potential predictor of prognosis in triple-negative breast cancer. (PMID:32432403)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	ldhba	ENSDARG00000019644
danio_rerio	ldhbb	ENSDARG00000071076
mus_musculus	Ldhb	ENSMUSG00000030246
rattus_norvegicus	Ldhb	ENSRNOG00000013000

Paralogs (5): LDHA (ENSG00000134333), MDH2 (ENSG00000146701), LDHC (ENSG00000166796), LDHAL6A (ENSG00000166800), LDHAL6B (ENSG00000171989)

Protein

Protein identifiers

L-lactate dehydrogenase B chain — P07195 (reviewed: P07195)

Alternative names: LDH heart subunit, Renal carcinoma antigen NY-REN-46

All UniProt accessions (6): P07195, A0A5F9ZHM4, A8MW50, C9J7H8, F5H793, Q5U077

UniProt curated annotations — full annotation on UniProt →

Function. Interconverts simultaneously and stereospecifically pyruvate and lactate with concomitant interconversion of NADH and NAD(+).

Subunit / interactions. Homotetramer. Interacts with PTEN upstream reading frame protein MP31; the interaction leads to inhibition of mitochondrial lactate dehydrogenase activity, preventing conversion of lactate to pyruvate in mitochondria.

Subcellular location. Cytoplasm. Mitochondrion inner membrane.

Tissue specificity. Predominantly expressed in aerobic tissues such as cardiac muscle.

Disease relevance. Lactate dehydrogenase B deficiency (LDHBD) [MIM:614128] A condition with no deleterious effects on health. LDHBD is of interest to laboratory medicine mainly because it can cause misdiagnosis in those disorders in which elevation of serum LDH is expected. The disease is caused by variants affecting the gene represented in this entry.

Pathway. Fermentation; pyruvate fermentation to lactate; (S)-lactate from pyruvate: step 1/1.

Similarity. Belongs to the LDH/MDH superfamily. LDH family.

RefSeq proteins (6): NP_001167568, NP_001302466, NP_001401162, NP_001401163, NP_001401164, NP_002291* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001236	Lactate/malate_DH_N	Domain
IPR001557	L-lactate/malate_DH	Family
IPR011304	L-lactate_DH	Family
IPR015955	Lactate_DH/Glyco_Ohase_4_C	Homologous_superfamily
IPR018177	L-lactate_DH_AS	Active_site
IPR022383	Lactate/malate_DH_C	Domain
IPR036291	NAD(P)-bd_dom_sf	Homologous_superfamily

Pfam: PF00056, PF02866

Enzyme classification (BRENDA):

• EC 1.1.1.27 — L-lactate dehydrogenase (BRENDA: 149 organisms, 178 substrates, 252 inhibitors, 294 Km, 98 kcat entries)

Substrate kinetics (BRENDA)

25 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
PYRUVATE	0.016–77	118
NADH	0.007–44	55
(S)-LACTATE	0.0018–1100	50
NAD+	0.0081–5	25
PHENYLPYRUVATE	1.76–8.23	6
3-ACETYLPYRIDINE ADENINE DINUCLEOTIDE	0.123–0.408	4
LACTATE	3.3–105.1	4
L-LACTATE	0.047–60	3
2-OXOBUTANOATE	77	1
2-OXOBUTYRATE	0.6	1
2-OXOVALERATE	0.116	1
3,4-DIHYDROXYPHENYLPYRUVATE	11.37	1
APAD+	0.0085	1
APADH	0.0166	1
GLYOXYLATE	25	1

Catalyzed reactions (Rhea), 1 shown:

• (S)-lactate + NAD(+) = pyruvate + NADH + H(+) (RHEA:23444)

UniProt features (64 total): helix 16, strand 14, sequence variant 13, modified residue 7, binding site 7, mutagenesis site 2, turn 2, initiator methionine 1, chain 1, active site 1

Structure

Experimental structures (PDB)

7 structures.

PDB	Method	Resolution (Å)
7DBJ	X-RAY DIFFRACTION	1.55
7DBK	X-RAY DIFFRACTION	1.8
9QYK	X-RAY DIFFRACTION	2.06
8S88	X-RAY DIFFRACTION	2.07
1I0Z	X-RAY DIFFRACTION	2.1
8QDE	X-RAY DIFFRACTION	2.98
1T2F	X-RAY DIFFRACTION	3

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P07195-F1	96.05	0.92

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 194 (proton acceptor)

Ligand- & substrate-binding residues (7): 31–53; 100; 107; 139; 139; 170; 249

Post-translational modifications (7): 2, 7, 44, 58, 119, 240, 329

Mutagenesis-validated functional residues (2):

Position	Phenotype
53	abolishes interaction with mp31.
100	abolishes interaction with mp31.

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-70268	Pyruvate metabolism
R-HSA-1428517	Aerobic respiration and respiratory electron transport
R-HSA-1430728	Metabolism

MSigDB gene sets: 344 (showing top): HORIUCHI_WTAP_TARGETS_DN, MODY_HIPPOCAMPUS_POSTNATAL, SP3_Q3, KEGG_CYSTEINE_AND_METHIONINE_METABOLISM, HSIAO_HOUSEKEEPING_GENES, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, KEGG_GLYCOLYSIS_GLUCONEOGENESIS, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, GOBP_NADPLUS_METABOLIC_PROCESS, RODWELL_AGING_KIDNEY_NO_BLOOD_DN, PUJANA_CHEK2_PCC_NETWORK, GOBP_NUCLEOBASE_CONTAINING_SMALL_MOLECULE_METABOLIC_PROCESS, NEBEN_AML_WITH_FLT3_OR_NRAS_DN, MARTINEZ_RB1_TARGETS_DN, KORKOLA_EMBRYONAL_CARCINOMA_UP

GO Biological Process (4): lactate metabolic process (GO:0006089), NAD+ metabolic process (GO:0019674), pyruvate catabolic process (GO:0042867), carboxylic acid metabolic process (GO:0019752)

GO Molecular Function (9): L-lactate dehydrogenase (NAD+) activity (GO:0004459), kinase binding (GO:0019900), identical protein binding (GO:0042802), NAD binding (GO:0051287), catalytic activity (GO:0003824), lactate dehydrogenase activity (GO:0004457), protein binding (GO:0005515), oxidoreductase activity (GO:0016491), oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor (GO:0016616)

GO Cellular Component (8): cytoplasm (GO:0005737), mitochondrion (GO:0005739), mitochondrial inner membrane (GO:0005743), cytosol (GO:0005829), membrane (GO:0016020), membrane raft (GO:0045121), extracellular exosome (GO:0070062), oxidoreductase complex (GO:1990204)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Aerobic respiration and respiratory electron transport	1
Metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
oxidoreductase activity, acting on CH-OH group of donors	2
cytoplasm	2
monocarboxylic acid metabolic process	1
purine nucleotide metabolic process	1
nicotinamide nucleotide metabolic process	1
pyruvate metabolic process	1
monocarboxylic acid catabolic process	1
oxoacid metabolic process	1
L-2-hydroxycarboxylate dehydrogenase (NAD+) activity	1
L-lactate dehydrogenase activity	1
enzyme binding	1
protein binding	1
adenyl nucleotide binding	1
molecular_function	1
binding	1
catalytic activity	1
intracellular anatomical structure	1
intracellular membrane-bounded organelle	1
organelle inner membrane	1
mitochondrial membrane	1
membrane microdomain	1
extracellular vesicle	1
catalytic complex	1

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

204 interactions, top by confidence:

A	B	Type	Score
LDHA	LDHB	psi-mi:“MI:0915”(physical association)	0.810
LDHB	LDHA	psi-mi:“MI:0915”(physical association)	0.810
LDHB	LDHB	psi-mi:“MI:0915”(physical association)	0.800
LDHA	LDHB	psi-mi:“MI:0914”(association)	0.800
LDHA	LDHB	psi-mi:“MI:0915”(physical association)	0.800
LDHB	LDHA	psi-mi:“MI:0914”(association)	0.800
LDHC	LDHA	psi-mi:“MI:0914”(association)	0.770
LDHB	LDHC	psi-mi:“MI:0915”(physical association)	0.740
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710

BioGRID (530): LDHB (Affinity Capture-MS), LDHB (Affinity Capture-MS), LDHB (Two-hybrid), LDHB (Two-hybrid), PEX5 (Two-hybrid), LDHB (Affinity Capture-MS), LDHB (Affinity Capture-MS), ACADM (Co-fractionation), ADSL (Co-fractionation), AHCY (Co-fractionation), ALDH1B1 (Co-fractionation), ALDH2 (Co-fractionation), ALDH4A1 (Co-fractionation), APRT (Co-fractionation), ARF4 (Co-fractionation)

ESM2 similar proteins: A0A1F3, A5A6N7, P00336, P00337, P00338, P00339, P00340, P00341, P04642, P06151, P07195, P13491, P13743, P16125, P19858, P33571, P42120, P42123, P69080, P69081, P69082, P79912, P79913, Q4R5B6, Q5E9B1, Q5R1W9, Q5R5F0, Q6DGK2, Q92055, Q98SK9, Q98SL0, Q98SL1, Q98SL2, Q9BE24, Q9PT42, Q9PT43, Q9PVK4, Q9PVK5, Q9PW04, Q9PW05

Diamond homologs: A0A1F3, A5A6N7, A5I1Z6, A7FU32, B1L1N3, C1FMZ1, O13276, O13277, O13278, O93401, O93537, O93538, O93539, O93540, O93541, O93542, O93543, O93544, O93545, O93546, P00336, P00337, P00338, P00339, P00340, P00341, P00342, P04642, P06151, P07195, P07864, P13490, P13491, P13743, P16125, P19629, P19858, P20373, P22988, P22989

SIGNOR signaling

6 interactions.

A	Effect	B	Mechanism
SIRT5	“up-regulates activity”	LDHB	deacetylation
“HIF-1 complex”	“up-regulates quantity”	LDHB	“transcriptional regulation”
LDHB	up-regulates	Glycolysis
LDHB	“down-regulates quantity”	pyruvate	“chemical modification”
LDHB	“up-regulates quantity”	(S)-lactate	“chemical modification”
AURKA	“up-regulates activity”	LDHB	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 173 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Dengue Virus Genome Translation and Replication	5	13.9×	7e-03
Signaling by Interleukins	11	6.2×	1e-03
Cytokine Signaling in Immune system	13	4.7×	2e-03

GO biological processes:

GO term	Partners	Fold	FDR
mitotic spindle organization	6	11.4×	7e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

68 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	40
Likely benign	2
Benign	6

Top pathogenic / likely-pathogenic (0)

SpliceAI

1040 predictions. Top by Δscore:

Variant	Effect	Δscore
12:21635706:TCCC:T	acceptor_gain	1.0000
12:21635707:CCCC:C	acceptor_gain	1.0000
12:21637066:CTTA:C	donor_loss	1.0000
12:21637067:TTA:T	donor_loss	1.0000
12:21637069:A:AC	donor_gain	1.0000
12:21637070:C:CA	donor_loss	1.0000
12:21637070:C:CC	donor_gain	1.0000
12:21637190:AGGCA:A	acceptor_gain	1.0000
12:21637191:GGCA:G	acceptor_gain	1.0000
12:21637192:GCA:G	acceptor_gain	1.0000
12:21637193:CA:C	acceptor_gain	1.0000
12:21637193:CACT:C	acceptor_gain	1.0000
12:21637195:C:CC	acceptor_gain	1.0000
12:21637196:T:C	acceptor_gain	1.0000
12:21637196:T:TC	acceptor_gain	1.0000
12:21638348:CTTA:C	donor_loss	1.0000
12:21638349:TTA:T	donor_loss	1.0000
12:21638350:TA:T	donor_loss	1.0000
12:21638351:A:AC	donor_gain	1.0000
12:21638351:AC:A	donor_gain	1.0000
12:21638351:ACCT:A	donor_loss	1.0000
12:21638352:C:CT	donor_gain	1.0000
12:21638352:CC:C	donor_gain	1.0000
12:21638352:CCT:C	donor_gain	1.0000
12:21638352:CCTTT:C	donor_gain	1.0000
12:21638377:T:TA	donor_gain	1.0000
12:21638466:AGCCA:A	acceptor_gain	1.0000
12:21638467:GCCA:G	acceptor_gain	1.0000
12:21638468:CCA:C	acceptor_gain	1.0000
12:21638468:CCAC:C	acceptor_gain	1.0000

AlphaMissense

2212 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:21637147:C:T	G254E	1.000
12:21637171:T:A	K246I	1.000
12:21641963:C:A	G195V	1.000
12:21641963:C:T	G195D	1.000
12:21641972:C:T	G192E	1.000
12:21641973:C:A	G192W	1.000
12:21642047:T:A	D167V	1.000
12:21642059:C:T	G163E	1.000
12:21642065:C:T	G161E	1.000
12:21643937:G:T	P140Q	1.000
12:21643938:G:A	P140S	1.000
12:21643939:G:C	N139K	1.000
12:21643939:G:T	N139K	1.000
12:21644027:A:G	L110P	1.000
12:21644063:C:T	G98E	1.000
12:21646965:C:G	G61R	1.000
12:21646965:C:T	G61R	1.000
12:21654583:C:T	G30E	1.000
12:21654589:C:T	G28D	1.000
12:21654590:C:G	G28R	1.000
12:21635597:A:G	L317P	0.999
12:21635674:G:C	S291R	0.999
12:21635674:G:T	S291R	0.999
12:21635676:T:G	S291R	0.999
12:21637140:A:C	S256R	0.999
12:21637140:A:T	S256R	0.999
12:21637142:T:G	S256R	0.999
12:21637147:C:A	G254V	0.999
12:21637148:C:G	G254R	0.999
12:21637148:C:T	G254R	0.999

dbSNP variants (sampled 300 via entrez): RS1000012958 (12:21634907 T>C), RS1000084922 (12:21648375 C>A), RS1000163602 (12:21644901 C>T), RS1000259015 (12:21645171 G>A,C), RS1000351214 (12:21638867 T>C), RS1000483938 (12:21645113 T>C,G), RS1000493454 (12:21651371 G>A), RS1000517764 (12:21644811 T>C), RS1000751510 (12:21651112 G>A), RS1000800300 (12:21657060 C>G), RS1000952309 (12:21656170 G>A), RS1001628845 (12:21658319 C>T), RS1001709545 (12:21644670 G>A), RS1001743962 (12:21650425 G>C), RS1001837512 (12:21646018 C>T)

Disease associations

OMIM: gene MIM:150100 | disease phenotypes: MIM:614128

GenCC curated gene-disease

Disease	Classification	Inheritance
glycogen storage disease due to lactate dehydrogenase H-subunit deficiency	Supportive	Autosomal dominant

Mondo (1): glycogen storage disease due to lactate dehydrogenase H-subunit deficiency (MONDO:0013587)

Orphanet (1): Glycogen storage disease due to lactate dehydrogenase H-subunit deficiency (Orphanet:284435)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0045041	Reduced circulating lactate dehydrogenase concentration

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST010396_213	Gut microbiota (bacterial taxa, hurdle binary method)	4.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0007874	gut microbiome measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
C563641	Lactate Dehydrogenase B Deficiency (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL4940 (SINGLE PROTEIN), CHEMBL5465228 (PROTEIN-PROTEIN INTERACTION)

Molecules with ChEMBL bioactivity

2 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 15,511 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL51483	GOSSYPOL	3	13,973
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

Binding affinities (BindingDB)

3 measured of 33 human assays (33 total across all organisms); most potent 3 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
GNE-140 (6)	IC50	3 nM
3-hydroxy-1,2-oxazole-4-carboxylic acid	IC50	54000 nM
4-hydroxy-1,2,5-oxadiazole-3-carboxylic acid	IC50	72000 nM

ChEMBL bioactivities

190 potent at pChembl≥5 of 279 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.77	IC50	1.7	nM	CHEMBL5185237
8.66	IC50	2.2	nM	CHEMBL5201115
8.55	IC50	2.8	nM	CHEMBL5181496
8.30	IC50	5	nM	CHEMBL4065858
8.30	IC50	5	nM	CHEMBL4753379
8.10	IC50	8	nM	CHEMBL4059985
8.09	IC50	8.2	nM	CHEMBL5196929
8.08	Kd	8.312	nM	CHEMBL3752910
8.08	ED50	8.312	nM	CHEMBL3752910
8.05	IC50	8.9	nM	CHEMBL5172378
8.02	IC50	9.5	nM	CHEMBL5194549
8.01	IC50	9.8	nM	CHEMBL5183539
7.82	IC50	15	nM	CHEMBL5181996
7.77	IC50	17	nM	CHEMBL5182266
7.70	IC50	20	nM	CHEMBL4090677
7.70	IC50	20	nM	CHEMBL4100845
7.60	IC50	25	nM	CHEMBL5188480
7.57	IC50	27	nM	CHEMBL4081890
7.52	IC50	30	nM	CHEMBL4436150
7.51	IC50	31	nM	CHEMBL5181496
7.47	IC50	34	nM	CHEMBL5202219
7.46	IC50	35	nM	CHEMBL4576717
7.46	IC50	35	nM	CHEMBL4467769
7.42	IC50	38	nM	CHEMBL5185237
7.37	IC50	43	nM	CHEMBL3335794
7.37	IC50	43	nM	CHEMBL5416627
7.34	IC50	46	nM	CHEMBL4536094
7.34	IC50	46	nM	CHEMBL5189879
7.33	IC50	47	nM	CHEMBL5177632
7.31	IC50	49	nM	CHEMBL4080497
7.31	IC50	49	nM	CHEMBL4520899
7.30	IC50	50	nM	CHEMBL4444963
7.30	Ki	50	nM	CHEMBL126519
7.26	IC50	55	nM	CHEMBL4453059
7.24	IC50	57	nM	CHEMBL4521960
7.24	IC50	57	nM	CHEMBL5196259
7.22	IC50	60	nM	CHEMBL4475593
7.21	IC50	62	nM	CHEMBL4101800
7.19	IC50	65	nM	CHEMBL5176448
7.17	IC50	68	nM	CHEMBL5182266
7.16	IC50	70	nM	CHEMBL4543949
7.12	IC50	75	nM	CHEMBL4075666
7.12	IC50	75	nM	CHEMBL4450897
7.12	IC50	75	nM	CHEMBL5189798
7.12	IC50	75	nM	CHEMBL5197729
7.11	IC50	78	nM	CHEMBL4076027
7.11	IC50	77	nM	CHEMBL4435570
7.10	IC50	80	nM	CHEMBL4543194
7.07	IC50	85	nM	CHEMBL5201115
7.05	IC50	90	nM	CHEMBL5181996

PubChem BioAssay actives

188 with measured affinity, of 541 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
5-(2-chlorophenyl)sulfanyl-2-[6-(4-fluoroanilino)-2-pyridinyl]-4-hydroxy-2-(4-morpholin-4-ylphenyl)-1,3-dihydropyridin-6-one	1882404: Inhibition of LDHB (unknown origin)	ic50	0.0017	uM
5-(2-chlorophenyl)sulfanyl-2-[6-(4-fluorophenoxy)-2-pyridinyl]-4-hydroxy-2-(4-morpholin-4-ylphenyl)-1,3-dihydropyridin-6-one	1882404: Inhibition of LDHB (unknown origin)	ic50	0.0022	uM
5-(2-chlorophenyl)sulfanyl-2-[6-(cyclohexylamino)-2-pyridinyl]-2-[6-(3,4-difluoroanilino)-2-pyridinyl]-4-hydroxy-1,3-dihydropyridin-6-one	1882404: Inhibition of LDHB (unknown origin)	ic50	0.0028	uM
(2R)-5-(2-chlorophenyl)sulfanyl-4-hydroxy-2-(4-morpholin-4-ylphenyl)-2-thiophen-3-yl-1,3-dihydropyridin-6-one	1631171: Inhibition of human recombinant carboxy-terminal His-tagged LDHB by UV endpoint assay	ic50	0.0050	uM
2-[5-(cyclopropylmethyl)-4-[(3-fluoro-4-sulfamoylphenyl)methyl]-3-[3-[2-(5-methylthiophen-2-yl)ethynyl]phenyl]pyrazol-1-yl]-1,3-thiazole-4-carboxylic acid	1964690: Inhibition of human LDHB	ic50	0.0050	uM
2-[5-(cyclopropylmethyl)-3-phenyl-4-[(4-sulfamoylphenyl)methyl]pyrazol-1-yl]-1,3-thiazole-4-carboxylic acid	1477149: Inhibition of human erythrocytes LDHB using sodium pyruvate as substrate after 5 mins in presence of NAPDH by diaphorase/resazurin based fluorescence assay	ic50	0.0080	uM
5-(2-chlorophenyl)sulfanyl-2-[6-(3,4-difluoroanilino)-2-pyridinyl]-4-hydroxy-2-[6-(oxan-4-ylamino)-2-pyridinyl]-1,3-dihydropyridin-6-one	1882404: Inhibition of LDHB (unknown origin)	ic50	0.0082	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148646: Binding affinity to human LDHB incubated for 45 mins by Kinobead based pull down assay	kd	0.0083	uM
2-(3-aminophenyl)-5-(2-chlorophenyl)sulfanyl-4-hydroxy-2-thiophen-3-yl-3H-pyran-6-one	1882404: Inhibition of LDHB (unknown origin)	ic50	0.0089	uM
5-(2-chlorophenyl)sulfanyl-2-[6-(3,4-difluoroanilino)-2-pyridinyl]-4-hydroxy-2-(6-phenoxy-2-pyridinyl)-1,3-dihydropyridin-6-one	1882404: Inhibition of LDHB (unknown origin)	ic50	0.0095	uM
(2R)-5-(2-chlorophenyl)sulfanyl-2-[6-(3,4-difluoroanilino)-2-pyridinyl]-2-[6-(4-fluoroanilino)-2-pyridinyl]-4-hydroxy-1,3-dihydropyridin-6-one	1882404: Inhibition of LDHB (unknown origin)	ic50	0.0098	uM
5-(2-chlorophenyl)sulfanyl-4-hydroxy-2-(2-hydroxyphenyl)-2-thiophen-3-yl-3H-pyran-6-one	1882404: Inhibition of LDHB (unknown origin)	ic50	0.0150	uM
5-(2-chlorophenyl)sulfanyl-2-[6-(4-fluoroanilino)-2-pyridinyl]-4-hydroxy-2-thiophen-3-yl-3H-pyran-6-one	1882404: Inhibition of LDHB (unknown origin)	ic50	0.0170	uM
2-[5-cyclopropyl-3-(3-phenylphenyl)-4-[(4-sulfamoylphenyl)methyl]pyrazol-1-yl]-1,3-thiazole-4-carboxylic acid	1477149: Inhibition of human erythrocytes LDHB using sodium pyruvate as substrate after 5 mins in presence of NAPDH by diaphorase/resazurin based fluorescence assay	ic50	0.0200	uM
2-[5-cyclopropyl-3-phenyl-4-[(4-sulfamoylphenyl)methyl]pyrazol-1-yl]-1,3-thiazole-4-carboxylic acid	1477149: Inhibition of human erythrocytes LDHB using sodium pyruvate as substrate after 5 mins in presence of NAPDH by diaphorase/resazurin based fluorescence assay	ic50	0.0200	uM
5-(2-chlorophenyl)sulfanyl-2-[6-(3,4-difluoroanilino)-2-pyridinyl]-4-hydroxy-2-(6-quinolin-5-yloxy-2-pyridinyl)-1,3-dihydropyridin-6-one	1882404: Inhibition of LDHB (unknown origin)	ic50	0.0250	uM
2-[5-(cyclopropylmethyl)-3-(3-phenylphenyl)-4-[(4-sulfamoylphenyl)methyl]pyrazol-1-yl]-1,3-thiazole-4-carboxylic acid	1477149: Inhibition of human erythrocytes LDHB using sodium pyruvate as substrate after 5 mins in presence of NAPDH by diaphorase/resazurin based fluorescence assay	ic50	0.0270	uM
5-(2-chlorophenyl)sulfanyl-4-hydroxy-2-(4-morpholin-4-ylphenyl)-2-thiophen-3-yl-1,3-dihydropyridin-6-one	1631171: Inhibition of human recombinant carboxy-terminal His-tagged LDHB by UV endpoint assay	ic50	0.0300	uM
5-(2-chlorophenyl)sulfanyl-2-[6-(3,4-difluoroanilino)-2-pyridinyl]-4-hydroxy-2-thiophen-3-yl-1,3-dihydropyridin-6-one	1882404: Inhibition of LDHB (unknown origin)	ic50	0.0340	uM
2-[4-(4-acetylpiperazin-1-yl)phenyl]-5-(2-chlorophenyl)sulfanyl-4-hydroxy-2-thiophen-3-yl-1,3-dihydropyridin-6-one	1631171: Inhibition of human recombinant carboxy-terminal His-tagged LDHB by UV endpoint assay	ic50	0.0350	uM
5-(2-chlorophenyl)sulfanyl-2-[3-(4-fluoroanilino)phenyl]-4-hydroxy-2-thiophen-3-yl-1,3-dihydropyridin-6-one	1631171: Inhibition of human recombinant carboxy-terminal His-tagged LDHB by UV endpoint assay	ic50	0.0350	uM
2-[5-(cyclopropylmethyl)-3-[3-[6-[[13-[[(2S)-3,3-dimethyl-1-[(2S,4R)-2-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methylcarbamoyl]-4-phenylmethoxypyrrolidin-1-yl]-1-oxobutan-2-yl]amino]-13-oxotridecanoyl]amino]hex-1-ynyl]phenyl]-4-[(4-sulfamoylphenyl)methyl]pyrazol-1-yl]-1,3-thiazole-4-carboxylic acid	1964688: Inhibition of recombinant human LDHB	ic50	0.0430	uM
3-[[3-(cyclopropylsulfamoyl)-7-(2,4-dimethoxypyrimidin-5-yl)quinolin-4-yl]amino]-5-(3,5-difluorophenoxy)benzoic acid	1276044: Competitive inhibition of human LDH1 in presence of NADH	ic50	0.0430	uM
5-(2-chlorophenyl)sulfanyl-2-[4-(1,1-dioxo-1,4-thiazinan-4-yl)phenyl]-4-hydroxy-2-thiophen-3-yl-1,3-dihydropyridin-6-one	1631171: Inhibition of human recombinant carboxy-terminal His-tagged LDHB by UV endpoint assay	ic50	0.0460	uM
(2S)-5-(2-chlorophenyl)sulfanyl-2-[6-(3,4-difluoroanilino)-2-pyridinyl]-2-[6-(4-fluoroanilino)-2-pyridinyl]-4-hydroxy-1,3-dihydropyridin-6-one	1882404: Inhibition of LDHB (unknown origin)	ic50	0.0460	uM
(2R)-5-(2-chlorophenyl)sulfanyl-2-[3-(4-fluoroanilino)phenyl]-4-hydroxy-2-thiophen-3-yl-3H-pyran-6-one	1882404: Inhibition of LDHB (unknown origin)	ic50	0.0470	uM
5-(2-chlorophenyl)sulfanyl-4-hydroxy-2-(4-piperidin-1-ylphenyl)-2-thiophen-3-yl-1,3-dihydropyridin-6-one	1631171: Inhibition of human recombinant carboxy-terminal His-tagged LDHB by UV endpoint assay	ic50	0.0490	uM
2-[3-(3-phenylphenyl)-4-[(4-sulfamoylphenyl)methyl]pyrazol-1-yl]-1,3-thiazole-4-carboxylic acid	1477149: Inhibition of human erythrocytes LDHB using sodium pyruvate as substrate after 5 mins in presence of NAPDH by diaphorase/resazurin based fluorescence assay	ic50	0.0490	uM
7-benzyl-2,3-dihydroxy-6-methyl-4-propylnaphthalene-1-carboxylic acid	99239: inhibitory activity against Human Lactate Dehydrogenase (LDH-M)	ki	0.0500	uM
5-(2-chlorophenyl)sulfanyl-4-hydroxy-2-(4-pyrrolidin-1-ylphenyl)-2-thiophen-3-yl-1,3-dihydropyridin-6-one	1631171: Inhibition of human recombinant carboxy-terminal His-tagged LDHB by UV endpoint assay	ic50	0.0500	uM
5-(2-chlorophenyl)sulfanyl-2-[4-(dimethylamino)phenyl]-4-hydroxy-2-thiophen-3-yl-1,3-dihydropyridin-6-one	1631171: Inhibition of human recombinant carboxy-terminal His-tagged LDHB by UV endpoint assay	ic50	0.0550	uM
5-(2-chlorophenyl)sulfanyl-4-hydroxy-2-(4-hydroxyphenyl)-2-thiophen-3-yl-1,3-dihydropyridin-6-one	1631171: Inhibition of human recombinant carboxy-terminal His-tagged LDHB by UV endpoint assay	ic50	0.0570	uM
5-(2-chlorophenyl)sulfanyl-2-[6-(3,4-difluoroanilino)-2-pyridinyl]-2-[6-[(4-fluorophenyl)methylamino]-2-pyridinyl]-4-hydroxy-1,3-dihydropyridin-6-one	1882404: Inhibition of LDHB (unknown origin)	ic50	0.0570	uM
1-[4-[5-(2-chlorophenyl)sulfanyl-4-hydroxy-6-oxo-2-thiophen-3-yl-1,3-dihydropyridin-2-yl]phenyl]piperidine-4-carbonitrile	1631171: Inhibition of human recombinant carboxy-terminal His-tagged LDHB by UV endpoint assay	ic50	0.0600	uM
2-[3-(3-phenylphenyl)-4-[(4-sulfamoylphenyl)methyl]-5-(trifluoromethyl)pyrazol-1-yl]-1,3-thiazole-4-carboxylic acid	1477149: Inhibition of human erythrocytes LDHB using sodium pyruvate as substrate after 5 mins in presence of NAPDH by diaphorase/resazurin based fluorescence assay	ic50	0.0620	uM
5-(2-chlorophenyl)sulfanyl-2-[3-[(5-fluoro-2-pyridinyl)amino]phenyl]-4-hydroxy-2-thiophen-3-yl-3H-pyran-6-one	1882404: Inhibition of LDHB (unknown origin)	ic50	0.0650	uM
5-(2-chlorophenyl)sulfanyl-2-[4-(2,2-dimethylmorpholin-4-yl)phenyl]-4-hydroxy-2-thiophen-3-yl-1,3-dihydropyridin-6-one	1631171: Inhibition of human recombinant carboxy-terminal His-tagged LDHB by UV endpoint assay	ic50	0.0700	uM
2-[5-amino-3-(3-phenylphenyl)-4-[(4-sulfamoylphenyl)methyl]pyrazol-1-yl]-1,3-thiazole-4-carboxylic acid	1477149: Inhibition of human erythrocytes LDHB using sodium pyruvate as substrate after 5 mins in presence of NAPDH by diaphorase/resazurin based fluorescence assay	ic50	0.0750	uM
5-(2-chlorophenyl)sulfanyl-4-hydroxy-2-[4-(4-methoxypiperidin-1-yl)phenyl]-2-thiophen-3-yl-1,3-dihydropyridin-6-one	1631171: Inhibition of human recombinant carboxy-terminal His-tagged LDHB by UV endpoint assay	ic50	0.0750	uM
5-(2-chlorophenyl)sulfanyl-4-hydroxy-2-(2-hydroxyphenyl)-2-phenyl-3H-pyran-6-one	1882404: Inhibition of LDHB (unknown origin)	ic50	0.0750	uM
(2S)-5-(2-chlorophenyl)sulfanyl-2-[3-(4-fluoroanilino)phenyl]-4-hydroxy-2-thiophen-3-yl-3H-pyran-6-one	1882404: Inhibition of LDHB (unknown origin)	ic50	0.0750	uM
5-(2-chlorophenyl)sulfanyl-2-[3-(cyclohexylamino)phenyl]-4-hydroxy-2-thiophen-3-yl-1,3-dihydropyridin-6-one	1631171: Inhibition of human recombinant carboxy-terminal His-tagged LDHB by UV endpoint assay	ic50	0.0770	uM
2-[3-(3-phenylphenyl)-4-(4-sulfamoylanilino)pyrazol-1-yl]-1,3-thiazole-4-carboxylic acid	1477149: Inhibition of human erythrocytes LDHB using sodium pyruvate as substrate after 5 mins in presence of NAPDH by diaphorase/resazurin based fluorescence assay	ic50	0.0780	uM
4-[4-[5-(2-chlorophenyl)sulfanyl-4-hydroxy-6-oxo-2-thiophen-3-yl-1,3-dihydropyridin-2-yl]phenyl]morpholin-3-one	1631171: Inhibition of human recombinant carboxy-terminal His-tagged LDHB by UV endpoint assay	ic50	0.0800	uM
2-[3-phenyl-4-(4-sulfamoylanilino)pyrazol-1-yl]-1,3-thiazole-4-carboxylic acid	1477149: Inhibition of human erythrocytes LDHB using sodium pyruvate as substrate after 5 mins in presence of NAPDH by diaphorase/resazurin based fluorescence assay	ic50	0.0960	uM
2,3-dihydroxy-6,7-dimethyl-4-propylnaphthalene-1-carboxylic acid	99239: inhibitory activity against Human Lactate Dehydrogenase (LDH-M)	ki	0.1000	uM
2-[5-cyclopropyl-3-(3-phenylphenyl)-4-(4-sulfamoylphenoxy)pyrazol-1-yl]-1,3-thiazole-4-carboxylic acid	1477149: Inhibition of human erythrocytes LDHB using sodium pyruvate as substrate after 5 mins in presence of NAPDH by diaphorase/resazurin based fluorescence assay	ic50	0.1190	uM
ethyl 2-[4-chloro-3-[4-(2,6-dichloro-3-phenylphenyl)-2-hydroxy-6-oxocyclohexen-1-yl]sulfanylphenyl]acetate	1227836: Inhibition of LDH-B (unknown origin)	ic50	0.1200	uM
2-[3-(3,4-difluorophenyl)-4-[(4-sulfamoylphenyl)methyl]pyrazol-1-yl]-1,3-thiazole-4-carboxylic acid	1477149: Inhibition of human erythrocytes LDHB using sodium pyruvate as substrate after 5 mins in presence of NAPDH by diaphorase/resazurin based fluorescence assay	ic50	0.1290	uM
2-[4-(2,6-dichloro-3-propan-2-yloxyphenyl)-2-hydroxy-6-oxocyclohexen-1-yl]sulfanyl-4-hydroxybenzonitrile	1227836: Inhibition of LDH-B (unknown origin)	ic50	0.1400	uM

CTD chemical–gene interactions

68 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases expression	3
Tobacco Smoke Pollution	affects expression, decreases expression, increases metabolic processing	3
bisphenol S	affects cotreatment, increases methylation, increases expression	2
Resveratrol	affects cotreatment, increases expression, affects secretion	2
Cyclosporine	increases expression, decreases expression	2
aristolochic acid I	decreases expression	1
bisphenol F	increases expression	1
TAK-243	increases sumoylation	1
chlorite	increases activity	1
bismuth tripotassium dicitrate	increases expression	1
bisphenol A	decreases expression	1
beta-lapachone	increases expression	1
arsenite	affects binding, decreases reaction, increases reaction	1
cobaltous chloride	decreases expression	1
acipimox	increases expression	1
triphenyltin	decreases expression	1
artenimol	affects binding	1
casticin	decreases expression	1
arsenic disulfide	decreases expression	1
tributyltinisothiocyanate	decreases expression	1
chloropicrin	increases expression	1
tanespimycin	increases expression	1
erucylphospho-N,N,N-trimethylpropylammonium	decreases expression	1
ICG 001	decreases expression	1
bisphenol B	increases expression	1
UCF 101	increases expression	1
bisphenol AF	increases expression	1
Arsenic Trioxide	decreases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Troglitazone	increases expression	1

ChEMBL screening assays

77 unique, capped per target: 73 binding, 3 admet, 1 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1692977	Binding	Inhibition of human LDH-B using pyruvate as substrate and NADH as cofactor at 125 uM after 5 mins by calorimetric assay relative to control	Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against cancer cells. — J Med Chem
CHEMBL3562094	Functional	PubChem BioAssay. Extended Characterization of HPGD Inhibitors: Counterscreen Against LDHB. (Class of assay: confirmatory)	PubChem BioAssay data set
CHEMBL4405922	ADMET	Binding affinity to recombinant full length human His-tagged LDH-1 (1 to 322 residues) expressed in Escherichia coli at 800 uM by WaterLOGSY NMR analysis	Interrogating the Lactate Dehydrogenase Tetramerization Site Using (Stapled) Peptides. — J Med Chem

Cellosaurus cell lines

3 cell lines: 2 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B3A4	Abcam HEK293T LDHB KO	Transformed cell line	Female
CVCL_E0VR	Ubigene Huh-7 LDHB KO	Cancer cell line	Male
CVCL_SV42	HAP1 LDHB (-)	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.